FindTrial
Sign In

Randomized controlled clinical trial investigating Erlotinib for the treatment of chronic hepatitis C virus infection

Randomized controlled clinical trial investigating Erlotinib for the treatment of chronic hepatitis C virus infection

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2012-002069-36-FR
Enrollment
Unknown
Registered
2013-06-25
Start date
2013-02-06
Completion date
Unknown
Last updated
2013-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C hepatitis MedDRA version: 14.1 Level: PT Classification code 10019755 Term: Hepatitis chronic active System Organ Class: 10019805 - Hepatobiliary disorders

Interventions

Trade Name: Tarceva 25mg comprimés pelliculés Pharmaceutical Form: Capsule INN or Proposed INN: ERLOTINIB HYDROCHLORIDE CAS Number: 183319-69-9 Concentration unit: mg milligram(s) Concentration type:

Sponsors

Hôpitaux Universitaires de Strasbourg
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 12 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: evaluating short term efficacy and safety of erlotinib in patient infected with genotype 1 C hepatitis virus ;Secondary Objective: - assessement of viral kinetic - erlotinib phamacokinitic evaluation - functional analysis of HCV quasispecies and viral resistance evaluation ;Primary end point(s):—

Countries

France

Contacts

Public ContactProject Manager

Hôpitaux Universitaires de Strasbourg

drci@chru-strasbourg.fr0033388115266

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026